Keros Therapeutics (NASDAQ:KROS) Insider Lorena Raquel Lerner Sells 3,568 Shares of Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) insider Lorena Raquel Lerner sold 3,568 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the sale, the insider owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. This represents a 11.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Keros Therapeutics Trading Down 1.4%

Keros Therapeutics stock opened at $10.95 on Friday. The firm’s fifty day moving average price is $10.69 and its two-hundred day moving average price is $11.85. The firm has a market capitalization of $217.11 million, a price-to-earnings ratio of -2.96 and a beta of 0.99. Keros Therapeutics, Inc. has a 1-year low of $9.69 and a 1-year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, research analysts forecast that Keros Therapeutics, Inc. will post -5.16 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors have recently modified their holdings of the company. Hsbc Holdings PLC raised its stake in shares of Keros Therapeutics by 29.5% during the second quarter. Hsbc Holdings PLC now owns 69,926 shares of the company’s stock worth $761,000 after acquiring an additional 15,940 shares in the last quarter. Nantahala Capital Management LLC bought a new position in shares of Keros Therapeutics during the 2nd quarter valued at $15,091,483,000. Empowered Funds LLC purchased a new position in Keros Therapeutics in the 2nd quarter worth $1,521,000. Public Employees Retirement System of Ohio purchased a new position in Keros Therapeutics in the 2nd quarter worth $538,000. Finally, Bank of America Corp DE bought a new stake in Keros Therapeutics in the second quarter worth $334,000. 71.56% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

KROS has been the topic of a number of recent analyst reports. Zacks Research lowered Keros Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 29th. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, August 16th. Leerink Partners decreased their price target on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Keros Therapeutics presently has a consensus rating of “Hold” and an average target price of $20.50.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.